share_log

iBio Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%), etc.

iBio Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%), etc.

iBio Inc | SC 13G/A:超過5%持股股東披露文件(修正)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%)等
美股SEC公告 ·  2024/11/14 22:52

Moomoo AI 已提取核心訊息

On November 14, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing indicated that ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, collectively reported shared voting and dispositive power over 966,298 shares of iBio Inc's common stock, representing 9.99% of the company's class. The shares include common stock and shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP, with certain ownership limitations in place. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was jointly signed by Daniel Schneeberger, who may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
On November 14, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing indicated that ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, collectively reported shared voting and dispositive power over 966,298 shares of iBio Inc's common stock, representing 9.99% of the company's class. The shares include common stock and shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP, with certain ownership limitations in place. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was jointly signed by Daniel Schneeberger, who may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
在2024年11月14日,ibio inc,一家生物技術公司,提交了一份Schedule 13G/A檔案給美國證券交易委員會。該文件顯示,ADAR1 Capital Management, LLC及其子公司ADAR1 Capital Management GP, LLC和Daniel Schneeberger共同報告對966,298股ibio inc普通股擁有共享投票權和處置權,佔該公司類股的9.99%。這些股份包括普通股和由ADAR1 Partners, LP持有的預融資和里程碑warrants所對應的股份,並且這些股份在某些所有權限制下。該文件根據1934年證券交易法第13d-1(b)條規...展開全部
在2024年11月14日,ibio inc,一家生物技術公司,提交了一份Schedule 13G/A檔案給美國證券交易委員會。該文件顯示,ADAR1 Capital Management, LLC及其子公司ADAR1 Capital Management GP, LLC和Daniel Schneeberger共同報告對966,298股ibio inc普通股擁有共享投票權和處置權,佔該公司類股的9.99%。這些股份包括普通股和由ADAR1 Partners, LP持有的預融資和里程碑warrants所對應的股份,並且這些股份在某些所有權限制下。該文件根據1934年證券交易法第13d-1(b)條規提交,表明這些股份是在正常的業務過程中收購的,並不是爲了改變或影響對ibio inc的控制權。報告人的主要業務辦公室位於德克薩斯州奧斯汀,該文件經Daniel Schneeberger共同簽署,他可能被視爲間接受益於ADAR1 Partners, LP和Spearhead Insurance Solutions IDF, LLC持有的證券。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息